Review PAPERS PRACE poglądowe Medical and ethical approach to acute coronary management of elderly patients – practical advice for primary care physicians Medyczne i etyczne aspekty postępowania ze starszymi pacjentami z ostrymi zespołami wieńcowymi – praktyczne rady dla lekarzy podstawowej opieki zdrowotnej Katarzyna Anna Rygiel Key words: acute coronary syndromes (ACS), elderly population, revascularization, risk–benefit ratio, left ventricular ejection fraction (LVEF), sudden cardiac death (SCD) Słowa kluczowe: ostry zespół wieńcowy (ACS), populacja starszych pacjentów, rewaskularyzacja, proporcja korzyści i ryzyka, frakcja wyrzutowa lewej komory (LVEF), nagła śmierć sercowa (SCD) Department of Family Medicine, Medical University of Silesia in Zabrze Katarzyna Anna Rygiel, MD, PhD Member of research and education team Abstract: Older age is an important risk factor that can determine outcomes in patients with acute coronary syndromes (ACS). However, research reports related to the practical use of invasive procedures and pharmacological therapies, reveal a lower use of these treatments among elderly patients. To facilitate an integrated approach to this problem in primary care setting, this article focuses on basic medical and ethical aspects of ACS. It offers some practical suggestions, how to improve therapeutic strategies for elderly patients, for family and primary care physicians, taking care of geriatric patients. It also focuses on management of elderly women with a high left ventricular ejection fraction (LVEF), who can have an elevated mortality risk, comparing to the ones with ACS, but with a normal LVEF. The article also highlights the main goal of the acute coronary management, which is to minimize risks, and to augment treatment benefits, within the individualized clinical, psycho-social, and family context. Streszczenie: Starszy wiek stanowi istotny czynnik ryzyka, determinujący rokowanie wśród pacjentów z ostrymi zespołami wieńcowymi (acute coronary syndrome, ACS). Jednakże raporty z badań klinicznych, dotyczące praktycznego zastosowania inwazyjnych procedur wieńcowych i terapii farmakologicznych, wykazują mniejszą częstość stosowania tego typu leczenia w starszej grupie pacjentów. Aby przybliżyć zintegrowany sposób podejścia klinicznego, w celu lepszego rozwiązania tego problemu w warunkach podstawowej opieki zdrowotnej (POZ), artykuł koncentruje się na zasadniczych medycznych i etycznych aspektach ACS oraz przedstawia praktyczne sugestie – jak poprawić strategie lecznicze w grupie geriatrycznych pacjentów, pozostających pod opieką lekarzy rodzinnych i praktyków POZ. Przeanalizowano także schemat postępowania w przypadku starszych kobiet z wysoką frakcją wyrzutową lewej komory serca (left ventricular ejection fraction, LVEF), wśród których może występować podwyższone ryzyko śmiertelności, w porównaniu z pacjentkami z ACS, u których stwierdzono prawidłową LVEF. W artykule podkreślono również, że głównym celem postępowania u starszych pacjentów z ACS jest minimalizacja ryzyka wieńcowego oraz zwiększenie korzyści terapeutycznych – w indywidualnym kontekście klinicznym, psychospołecznym i rodzinnym danego pacjenta. (Probl Med Rodz 2012;3(39):44–48) Introduction Coronary heart disease (CHD) is the leading cause of death all over the world, with higher rates CORRESPONDENCE ADDRESS: of mortality among women than men1. Elderly dr med. Katarzyna Anna Rygiel women with acute coronary syndrome (ACS) Katedra i Zakład Medycyny Rodzinnej Śląski Uniwersytet Medyczny current evidence indicates that women seek car- ul. 3 Maja 13/15 41-800 Zabrze [email protected] RECEIVED: 14.01.2012 ACCEPTED: 03.04.2012 44 have particularly high cardiovascular risk 2. Also, diac care less frequently, and are less likely to be promptly and properly diagnosed and treated, comparing to men3. Recently, a lot of reports, related to the practical use of invasive procedures and pharmacological therapies, have revealed a lower use of these treatments, among elderly patients (especially women), including the ones, who could have a real chance to benefit. This might be in part due to scarcity of research data on the details of care in geriatric population that is often excluded from clinical studies3. Thus, future trials should enroll the elderly in proper proportion to their representation in the general population. In the context of age-related changes in physiology and greater number of comorbid diseases, or previous cardiac procedures, treatment risks of the elderly patients with acute coronary syndromes PROBLEMY MEDYCYNY RODZINNEJ, SEPTEMBER 2012, VOL. XIV, No. 3 review PAPERS PRACE poglądowe (ACS) may often overshadow benefits, which are closely related to the patient-oriented management goals. These topics definitely merit further exploring, via modern research, in order to bridge many of the existing gaps in coronary care of the older population. In the initial presentation and treatment of ACS (including ST-segment elevation myocardial infarction – STEMI and non-ST-segment elevation myocardial infarction – nonSTEMI) among the elderly patients it is crucial to consider the role of comorbidities and concomitant medications, as well as the patient’s needs, expectations, psycho-social functional level, ethical issues, comfort level, and availability of care. Family and primary care physicians are usually involved in some aspects of coordination of these complex management issues. Physiological differences contributing to undesirable coronary outcomes in elderly patients Studies have shown that morbidity and mortality rates in patients with myocardial infarction increase with age4,5. For instance, in the GUSTO-I trial, the 30-day mortality rate increased 10-fold, from 3.0% among patients younger than 65 years to 30.3% among the ones older than 85 years4. The age-related lethal complications can be explained by some physiological changes in heart and blood vessels such as: •ventricular hypertrophy and remodeling, •decreased vascular compliance6. The most serious, age-related cardiovascular complications include: •heart failure and pulmonary edema – that occur in over 50% of patients older than 75 years, and in over 65% of patients older than 85 years7, •cardiogenic shock, manifested by hypotension and hypoperfusion – that occurs in more than 10% of patients older than 75 years, and is usually secondary to ventricular or papillary muscle rupture or to ventricular dysfunction8,9. In addition, myocardial edema and hemorrhage can often be found on autopsy of the elderly patients, who received fibrinolytic therapy10. The proportion of patients eligible for reperfusion decreases with advanced age. Also, elderly STEMI patients are still less likely to receive reperfusion (percutaneous coronary intervention – PCI or fibrinolytic therapy) even if they are eligible. Moreover, many elderly present with atypical symptoms, previous abnormalities on ECGs, or comorbidities that may obscure their clinical PROBLEMY MEDYCYNY RODZINNEJ, SEPTEMBER 2012, VOL. XIV, No. 3 picture, making their treatment more difficult. In this way, the elderly have a higher likelihood of death after STEMI, which can be attributed to diastolic or systolic dysfunction, causing heart failure. Benefits of PCI versus fibrinolytic therapy in the elderly population Based on randomized trials, meta-analyses, and observational studies, risk-benefit ratio favors PCI over fibrinolytic therapy in the elderly11,12. Although, more data are needed in patients above 80 years of age, the following findings have been reported: •the main benefit from PCI is a reduction in reinfarction and need for target-vessel revascularization, as well as mortality reduction, •adjusting the dose of adjunctive antithrombin agents with fibrinolytic therapy improves outcome, •availability and time to reperfusion are key determinants of myocardial salvage and clinical benefits, regardless of the applied strategy, •PCI can be applied without ST-segment elevation or ongoing chest pain and is preferable in the setting of shock or high TIMI risk scores. According to the GRACE registry, patients above 70 years of age, who underwent PCI versus fibrinolytic therapy had less reinfarction and death11. Similarly, based on the Cooperative Cardiovascular Project database, among patients above 65 years of age, PCI was associated with modest short- or long-term mortality benefits compared with fibrinolytic therapy12. The timing and availability of PCI often involve emergency transfers to a PCI-capable cardiac care facility, and this transfer should be considered for the elderly patients: •at high risk, who present with cardiogenic shock or arrive more than 3 hours from their symptom onset, •with contraindications to fibrinolytic therapy, particularly if the “door to balloon” time is less than 90 minutes. Unfortunately, the mortality rate for STEMI patients with cardiogenic shock is still high regardless of reperfusion methods13. Elderly women with a high left ventricular ejection fraction (LVEF) Depressed left ventricular function, complicating an ACS, can independently predicts poor outcome14. Based on previous research, it was reported that the mortality rates were highest among patients with the low ejection fraction (EF). 45 review PAPERS PRACE poglądowe However, according to a recent study, it was found that the elderly women with a high EF had a higher mortality rate than the ones, who had a normal EF15. In general, elderly women with an EF >55% are considered to have normal systolic function. However, despite having a normal systolic function, they more often suffer from the diastolic dysfunction, compared with elderly men16. This can be due to aging process, often associated with arterial hypertension, myocardial ischemia or infarction, as contributors to diastolic failure17. It was reported that the patients with diastolic dysfunction, and without CHD had a relatively good prognosis18. However, in elderly women with an ACS, who had a high left ventricular ejection fraction (LVEF) (>65%), there was an association with higher rates of sudden cardiac death (SCD). This correlation was higher comparing to those older female patients, whose LVEF was considered to be in the normal range. This phenomenon may be related to the fact that after ACS (e.g.: acute myocardial infarction – AMI), ventricular function depends on multiple factors, including: •infarct size, •location, •left ventricular contractility at the infracted area19. According to evidence from clinical trials, the use of intracardiac defibrillators for the prevention of SCD and sustained ventricular tachycardia among patients with severely depressed LVEF (e.g.: post AMI, with EF <35%), has been recommended19. However, some recent reports suggest that a severely depressed left ventricular function might not be present in many patients, who suffered from sudden death. In particular, a large, population-based study has revealed that a majority of sudden cardiac death patients did not have the severely diminished left ventricular function20. Moreover, in a community-based study, researchers have found that only 19% of SCD victims had diminished their LVEF, defined as <30%21. Elderly women with hypertrophic hearts and a high LVEF may be particularly susceptible to oxygen supply-mediated myocardial ischemia. It appears that there is an association between ACS/AMI and SCD, due to ischemia-mediated ventricular tachycardia or ventricular fibrillation22. This evidence could impact the physician’s decision making, related to the diagnostic work-up, which can better identify patients at risk for SCD after ACS (e.g.: electrophysiology study). However, the implication of these results, with regard to the practical patient management merits further exploration in research trials. 46 Adjunctive pharmacotherapy in the elderly patients The following short- and long-term benefits of adjunctive pharmacotherapy have been found among the elderly patients: •ß-blockers have greater benefits in the elderly patients for the prevention of subsequent MI and death than in younger groups. However, given the potential hypotensive and bradycardic adverse effects of intravenous ß-blockers, their use in STEMI with hemodynamic compromise is contraindicated. •ACE (angiotensin converting enzyme) inhibitors and angiotensin receptor blockers (ARB) are beneficial in the elderly, particularly in heart failure or reduced left ventricular function. •Statins have benefits in the elderly for the prevention of subsequent MI. •Nitrates may be useful in the elderly, because of their effects on preload, afterload, and reducing recurrent myocardial ischemia22. Medical ethics and acute cardiac care of the elderly Ethical uncertainty in the acute coronary care of the elderly often arises from the limited evidence base and multiplicity of patient preferences or other relevant clinical or personal circumstances23. There is no doubt that the interventions with questionable benefit or significant risk of harm should be avoided. Of course, more data regarding risk and benefit of different interventions among the elderly (above 75 years of age), and quality-of-life issues are still needed, in order to allow both elderly patients and their families to make informed decisions about their •acute, hospital-based treatment, •follow-up rehabilitation, •post-discharge home care. These additional information would facilitate the care rendered by cardiology specialists, in collaboration with family and primary care physicians, to growing elderly population with ACS. Some patients may not desire certain aggressive treatment methods or “heroic efforts”, especially in face of overall poor prognosis. At this point, their wishes should be respected. As always, a sound clinical judgment is very important in achieving the most optimal outcomes among elderly population in a cost-effective and patient-centered way. Also, more data on quality-of-life outcomes are needed. It appears that the elderly individuals should: PROBLEMY MEDYCYNY RODZINNEJ, SEPTEMBER 2012, VOL. XIV, No. 3 review PAPERS PRACE poglądowe •engage in conversations with loved ones about health preferences well in advance of their potential, and sometimes predictable healthcare crisis, •be encouraged to prepare their healthcare wishes and advanced directives (oral or written such as a “living will”), as paramount documentation, for guiding and ensuring autonomous care. On the other hand, discussing risk-benefit ratio or patient’s preferences in the acute care setting can often be challenging or hectic. Summary The main challenges in management of ACS in the elderly population are related to patient atypical presentations, advanced comorbidities, delayed arrival to specialistic cardiology centers, and limited research data, since geriatric patients are often excluded from clinical trials. Even though the eligibility for reperfusion declines with age, the elderly patients are less likely to receive reperfusion, even if they meet those criteria. There is a general agreement that the benefit associated with reperfusion is substantial in patients younger than 85 years, and a choice of fibrinolytics vs. PCI is determined by the time from presentation, comorbidities, or presence of cardiogenic shock (that may be indication for PCI). The safety and efficacy of reperfusion (especially fibrinolytic therapy) among elderly patients above 85 years of age remains questionable and requires further research, including information from ACS registries and clinical trials. In the elderly with ACS, the most important care topics are related to the: •benefit-risk ratio of invasive treatments and newer medications in context of physiological changes in advanced age and comorbidities, •selection criteria and doses of various medications or adjunctive treatments, •management of complications and interactions of medications, •quality-of-life outcomes, •patients’ choices, needs or wishes with relation to their level of psycho-physical functioning. In elderly women with an ACS, poor left ventricular systolic function has traditionally been associated with the worst outcomes. However, according to a recent study, some elderly women with preserved left ventricular function, those who had a high EF, experienced a 2-fold increased risk of mortality, cardiac arrest or ventricular fibrillation, comparing to those, who had a normal left ventricular ejection fraction PROBLEMY MEDYCYNY RODZINNEJ, SEPTEMBER 2012, VOL. XIV, No. 3 (LVEF). Of course, these findings need to be explored and confirmed in further clinical studies. In the meantime, local community registries are helpful in assessment of risks and benefits of acute care in the elderly patients, in real-world hospital practice. There is no doubt that the efficient communication between cardiologists, ambulance and hospital personnel, and family or primary care physicians, who are familiar with many aspects of the patient’s condition, is essential. In addition, some standard procedures, designed to reduce pre-hospital delays in detection, proper diagnosis, transfer, and treatment of ACS in the elderly need to be improved. Also, an important message to family and primary care physicians is that a common “one-size-fits-all” approach to the management of elderly patients is not appropriate in this heterogeneous population. Moreover, it is not acceptable due to many ethical reasons or dilemmas. Also, some potential treatment outcomes, related to the quality of life, physical, mental and emotional status, as well as ability to function independently need to be considered individually, based on long-term doctor-patient relationships in the primary care setting. After stabilization of the patient’s condition, during his/her hospital stay, and then post-discharge, the following mnemonic – ABCDE – might be helpful, as follow-up strategy: A = Aspirin, ACEI, ARB, and antianginals B = Beta-blockers and BP control C = Cholesterol level and cigarettes smoking cessation D = Diet and diabetes mellitus care E = Education and exercises List of abbreviations: ACEI – angiotensin converting enzyme inhibitors; ACS – acute coronary syndrome; AMI – acute myocardial infarction; ARB – angiotensin receptor blockers; CHD – coronary heart disease; CHF – chronic heart failure, congestive heart failure; CVD – cardiovascular disease; ECG or EKG – electrocardiogram; EF – ejection fraction; LVEF – left ventricular ejection fraction; MI – myocardial infarction; NSTEMI – non-ST segment elevation myocardial infarc tion; PCI – percutaneous coronary intervention; SCD – sudden cardiac death; STEMI – ST-elevation myocardial infarction; UA – unstable angina. 47 review PAPERS PRACE poglądowe References: 1. Roger VL, Jacobsen SJ, Pellikka PA, et al. Gender differences in use of stress testing and coronary heart disease mortality: a population based study in Olmsted County, Minnesota. J Am Coll Cardiol 1998;32:345– 352. 2. Covinsky KE, Chren MM, Harper DL, et al. Differences in patient-reported processes and outcomes between men and women with myocardial infarction. J Gen Intern Med 2000;15:169–174. 9. Menon V, Webb JG, Hillis LD, Sleeper LA, Abboud R, Dzavik V, et al. Outcome and profile of ventricular septal rupture with cardiogenic shock after myocardial infarction: a report from the SHOCK Trial Registry: SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK? J Am Coll Cardiol 2000;36 (suppl A):1110–1116. 3. Gibler WB, Armstrong PW, Ohman EM, et al. Persistence of delays in presentation and treatment for patients with acute myocardial infarction: the GUSTO-I and GUSTO-III experience. Ann Emerg Med 2002;39:123–130. 10. Bueno H, Martinez-Selles M, Perez-David E, LopezPalop R. Effect of thrombolytic therapy on the risk of cardiac rupture and mortality in older patients with first acute myocardial infarction. Eur Heart J 2005;26:1705–1711. 4. White HD, Barbash GI, Califf RM, Simes RJ, Granger CB, Weaver WD, et al. Age and outcome with contemporary thrombolytic therapy: results from the GUSTO-I trial: Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries Trial. Circulation 1996;94:1826–1833. 11. Mehta RH, Sadiq I, Goldberg RJ, Gore JM, Avezum A, Spencer F, Kline-Rogers E, Allegrone J, Pieper K, Fox KA, Eagle KA; GRACE Investigators. Effectiveness of primary percutaneous coronary intervention compared with that of thrombolytic therapy in elderly patients with acute myocardial infarction. Am Heart J 2004;147:253–259. 5. Maggioni AP, Maseri A, Fresco C, Franzosi MG, Mauri F, Santoro E, Tognoni G; The Investigators of the Gruppo Italiano per lo Studio della Sopravvivenza nell Infarto Miocardico (GISSI-2). Age-related increase in mortality among patients with first myocardial infarction treated with thrombolysis. N Engl J Med 1993;329:1442– 1448. 6. Goldberg RJ, Gore JM, Gurwitz JH, Alpert JS, Brady P, Strohsnitter W, Chen ZY, Dalen JE. The impact of age on the incidence and prognosis of initial acute myocardial infarction: the Worcester Heart Attack Study. Am Heart J 1989;117:543–549. 7. Mehta RH, Rathore SS, Radford MJ, Wang Y, Wang Y, Krumholz HM. Acute myocardial infarction in the elderly: differences by age. J Am Coll Cardiol 2001;38:736– 741. 8. Thompson CR, Buller CE, Sleeper LA, Antonelli TA, Webb JG, Jaber WA, Abel JG, Hochman JS. Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: a report from the SHOCK Trial Registry: SHould we use emergently revascularize Occluded Coronaries in cardiogenic 48 shocK? J Am Coll Cardiol 2000;36 (suppl A):1104– 1109. 12. Berger AK, Schulman KA, Gersh BJ, Pirzada S, Breall JA, Johnson AE, Every NR. Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients. JAMA 1999;282:341–348. 13. Hochman JS, Buller CE, Sleeper LA, Boland J, Dzavik V, Sanborn TA, Godfrey E, White HD, Lim J, LeJemtel T. Cardiogenic shock complicating acute myocardial infarction-etiologies, management and outcome: a report from the SHOCK Trial Registry: SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000;36 (suppl A):1063–1070. 14. Spencer FA, Meyer TE, Gore JM, et al. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure: the National Registry of Myocardial Infarction. Circulation 2002;105:2605–2610. 15. Saab FA, Steg PG, Avezum A, López-Sendón J, Anderson FA, Huang W, Eagle KA. Can an Elderly Woman’s Heart be too Strong? Increased Mortality with High versus Normal Ejection Fraction after an Acute Coronary Syndrome. The Global Registry of Acute Coronary Events. Am Heart J 2010;160(5):849–854. 16. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999;33:1948–1955. 17. Smith VE, Schulman P, Karimeddini MK, et al. Rapid ventricular filling in left ventricular hypertrophy: II. Pathologic hypertrophy. J Am Coll Cardiol 1985;5:869–874. 18. Brady J, Dwyer EM. Prognosis of patients with left ventricular diastolic pressure abnormality: a long-term survival study in patients without coronary artery disease. Clin Cardiol 2006;29:121–124. 19. Richter S, Duray G, Gronefeld G, et al. Prevention of sudden cardiac death: lessons from recent controlled trials. Circ J 2005;69:625–629. 20. Stecker EC, Vickers C, Waltz J, et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol 2006;47:1161–1166. 21. Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, et al. Out-of-hospital cardiac arrest – the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J 2003;24:1204–1209. 22. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473–1482. 23. Alexander KP, Newby LK, Armstrong PW, Cannon CP, Gibler WB, Rich MW, et al. Acute Coronary Care in the Elderly, Part II. ST-Segment Elevation Myocardial Infarction: A Scientific Statement for Healthcare Professionals from the American Heart Association Council on Clinical Cardiology: In Collaboration with the Society of Geriatric Cardiology. Circulation 2007;115:2570–2589. PROBLEMY MEDYCYNY RODZINNEJ, SEPTEMBER 2012, VOL. XIV, No. 3
© Copyright 2024